118 related articles for article (PubMed ID: 38588328)
21. DFO-Km: A Modular Chelator as a New Chemical Tool for the Construction of Zirconium-89-Based Radiopharmaceuticals.
Salih AK; Dominguez Garcia M; Raheem SJ; Ahiahonu WK; Price EW
Inorg Chem; 2023 Dec; 62(50):20806-20819. PubMed ID: 37751491
[TBL] [Abstract][Full Text] [Related]
22. Albumin-Binding PSMA Ligands: Optimization of the Tissue Distribution Profile.
Benešová M; Umbricht CA; Schibli R; Müller C
Mol Pharm; 2018 Mar; 15(3):934-946. PubMed ID: 29400475
[TBL] [Abstract][Full Text] [Related]
23. Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma.
Foster A; Nigam S; Tatum DS; Raphael I; Xu J; Kumar R; Plakseychuk E; Latoche JD; Vincze S; Li B; Giri R; McCarl LH; Edinger R; Ak M; Peddagangireddy V; Foley LM; Hitchens TK; Colen RR; Pollack IF; Panigrahy A; Magda D; Anderson CJ; Edwards WB; Kohanbash G
EBioMedicine; 2021 Sep; 71():103571. PubMed ID: 34530385
[TBL] [Abstract][Full Text] [Related]
24. Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model.
Song IH; Jeong MS; Hong HJ; Shin JI; Park YS; Woo SK; Moon BS; Kim KI; Lee YJ; Kang JH; Lee TS
Clin Cancer Res; 2019 Oct; 25(20):6148-6159. PubMed ID: 31337646
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
26. Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept.
Rondon A; Schmitt S; Briat A; Ty N; Maigne L; Quintana M; Membreno R; Zeglis BM; Navarro-Teulon I; Pouget JP; Chezal JM; Miot-Noirault E; Moreau E; Degoul F
Theranostics; 2019; 9(22):6706-6718. PubMed ID: 31588245
[No Abstract] [Full Text] [Related]
27. Radiolabeled F(ab')
Bellaye PS; Moreau M; Raguin O; Oudot A; Bernhard C; Vrigneaud JM; Dumont L; Vandroux D; Denat F; Cochet A; Brunotte F; Collin B
Clin Transl Oncol; 2018 Dec; 20(12):1557-1570. PubMed ID: 29777377
[TBL] [Abstract][Full Text] [Related]
28. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results.
Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP
J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272
[TBL] [Abstract][Full Text] [Related]
29.
Kuo HT; Lin KS; Zhang Z; Uribe CF; Merkens H; Zhang C; Bénard F
J Nucl Med; 2021 Apr; 62(4):521-527. PubMed ID: 32859704
[TBL] [Abstract][Full Text] [Related]
30. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
31. Improving Theranostic Gallium-68/Lutetium-177-Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer.
Lee BS; Kim MH; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim HS; Kim MH; Kil HS; Han SJ; Lee YJ; Lee KC; Lim SM; Chi DY
Mol Cancer Ther; 2021 Dec; 20(12):2410-2419. PubMed ID: 34725194
[TBL] [Abstract][Full Text] [Related]
32. Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect.
Goos JACM; Cho A; Carter LM; Dilling TR; Davydova M; Mandleywala K; Puttick S; Gupta A; Price WS; Quinn JF; Whittaker MR; Lewis JS; Davis TP
Theranostics; 2020; 10(2):567-584. PubMed ID: 31903138
[TBL] [Abstract][Full Text] [Related]
33. Targeting angiogenesis for radioimmunotherapy with a
Ehlerding EB; Lacognata S; Jiang D; Ferreira CA; Goel S; Hernandez R; Jeffery JJ; Theuer CP; Cai W
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):123-131. PubMed ID: 28821931
[TBL] [Abstract][Full Text] [Related]
34. Probody Therapeutic Design of
Giesen D; Broer LN; Lub-de Hooge MN; Popova I; Howng B; Nguyen M; Vasiljeva O; de Vries EGE; Pool M
Clin Cancer Res; 2020 Aug; 26(15):3999-4009. PubMed ID: 31953313
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
36. Biodistribution and pharmacokinetics of [
García-Varela L; Codesido J; Perez-Pedrosa A; Muñoz-González M; Ramos-Docampo E; Rey-Bretal D; García-Otero X; Gómez-Lado N; Turrero A; Beiroa D; Rodríguez-Perez AI; Vidal A; Fernández-Ferreiro A; Pubul V; Aguiar P
Int J Pharm; 2024 Mar; 652():123795. PubMed ID: 38224761
[TBL] [Abstract][Full Text] [Related]
37. Molecular imaging of T cell co-regulator factor B7-H3 with
Burvenich IJG; Parakh S; Lee FT; Guo N; Liu Z; Gan HK; Rigopoulos A; O'Keefe GJ; Gong SJ; Goh YW; Tochon-Danguy H; Scott FE; Kotsuma M; Hirotani K; Senaldi G; Scott AM
Theranostics; 2018; 8(15):4199-4209. PubMed ID: 30128047
[TBL] [Abstract][Full Text] [Related]
38. Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
Song IH; Lee TS; Park YS; Lee JS; Lee BC; Moon BS; An GI; Lee HW; Kim KI; Lee YJ; Kang JH; Lim SM
J Nucl Med; 2016 Jul; 57(7):1105-11. PubMed ID: 26917708
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor Models.
Jansen MH; Lagerweij T; Sewing AC; Vugts DJ; van Vuurden DG; Molthoff CF; Caretti V; Veringa SJ; Petersen N; Carcaboso AM; Noske DP; Vandertop WP; Wesseling P; van Dongen GA; Kaspers GJ; Hulleman E
Mol Cancer Ther; 2016 Sep; 15(9):2166-74. PubMed ID: 27325687
[TBL] [Abstract][Full Text] [Related]
40. Positron Emission Tomography Imaging of Platelet-Derived Growth Factor Receptor β in Colorectal Tumor Xenograft Using Zirconium-89 Labeled Dimeric Affibody Molecule.
Cai H; Shi Q; Tang Y; Chen L; Chen Y; Tao Z; Yang H; Xie F; Wu X; Liu N; Yang Y; Wu H; Tian R; Lu X; Li L
Mol Pharm; 2019 May; 16(5):1950-1957. PubMed ID: 30986347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
